Roncella S, Baldi L, Cutrona G, Viale M, Rizzo F, Gasco M, Ferrarini M, Pistoia V
Services of Clinical Immunology, National Institute for Cancer Research, Genoa, Italy.
Clin Immunol Immunopathol. 1995 Nov;77(2):162-71. doi: 10.1006/clin.1995.1139.
In this study we have raised spontaneous Epstein-Barr virus (EBV)-positive lymphoblastoid cell lines (LCL) from the peripheral blood of human immunodeficiency virus (HIV)-infected individuals and of control patients with primary EBV infections. These LCLs were also raised in the presence of the viral inhibitor phosphonoformate (PFA); under these conditions, the in vitro infection of bystander B lymphocytes with EBV released in culture by in vivo infected B cells is inhibited. Thus, the latter LCLs are likely to represent the progeny of B cells latently infected by EBV in vivo. The LCLs raised in the presence or absence of PFA had the same phenotypic features, type of EBV latency, and growth pattern irrespective of whether they had been raised from HIV-seropositive individuals or patients with primary EBV infections or had been generated by infecting normal B cells in vitro. Studies on the production of inflammatory cytokines were conducted by Northern blotting or by determining the cytokine concentrations in the cell supernatants by immunoassays or bioassays. Three of eight LCLs from HIV-seropositive patients released TNF alpha and 5/5 released TNF beta, IL6 was present in the supernatants of 1/8 LCLs, and IL1 alpha and IL1 beta were not detected in any culture supernatant. No differences were noticed in the patterns of cytokine secretion among the LCLs from HIV-seropositive patients and in those raised from patients with primary EBV infections or obtained by infecting normal B cells in vitro with EBV. It is tempting to speculate that abnormally expanded EBV-harboring B cells in HIV-seropositive patients may participate in the pathogenesis of certain clinical manifestations by releasing inflammatory cytokines; some of these cytokines might also contribute to the in vivo spreading of HIV infection. However, the spontaneous LCLs from HIV-seropositive individuals do not display abnormal features compared to latently EBV-infected LCLs from other sources despite the high frequency of EBV-driven lymphoproliferative disorders observed in AIDS patients.
在本研究中,我们从人类免疫缺陷病毒(HIV)感染个体以及原发性EB病毒(EBV)感染的对照患者的外周血中培养出了自发性EBV阳性淋巴母细胞系(LCL)。这些LCL也是在病毒抑制剂膦甲酸(PFA)存在的情况下培养出来的;在这些条件下,体内感染的B细胞在培养物中释放的EBV对旁观者B淋巴细胞的体外感染受到抑制。因此,后者的LCL可能代表体内被EBV潜伏感染的B细胞的后代。无论是否在PFA存在的情况下培养,也无论它们是从HIV血清阳性个体、原发性EBV感染患者中培养出来的,还是通过体外感染正常B细胞产生的,这些LCL都具有相同的表型特征、EBV潜伏类型和生长模式。通过Northern印迹法或通过免疫测定或生物测定法测定细胞上清液中的细胞因子浓度来进行炎症细胞因子产生的研究。来自HIV血清阳性患者的8个LCL中有3个释放肿瘤坏死因子α(TNFα),5/5释放肿瘤坏死因子β(TNFβ),1/8的LCL上清液中存在白细胞介素6(IL6),而在任何培养上清液中均未检测到白细胞介素1α(IL1α)和白细胞介素1β(IL1β)。在来自HIV血清阳性患者的LCL以及来自原发性EBV感染患者或通过体外EBV感染正常B细胞获得的LCL之间,未观察到细胞因子分泌模式的差异。有一种推测很有吸引力,即HIV血清阳性患者中异常扩增的携带EBV的B细胞可能通过释放炎症细胞因子参与某些临床表现的发病机制;其中一些细胞因子也可能有助于HIV感染在体内的传播。然而,尽管在艾滋病患者中观察到EBV驱动的淋巴增殖性疾病的发生率很高,但来自HIV血清阳性个体的自发性LCL与来自其他来源的潜伏性EBV感染的LCL相比,并未表现出异常特征。